Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
2.800
+0.010 (0.36%)
At close: Aug 7, 2026, 4:00 PM EDT
2.600
-0.200 (-7.14%)
After-hours: Aug 7, 2026, 7:34 PM EDT
Radiopharm Theranostics Revenue
Radiopharm Theranostics had revenue of 6.20M AUD in the half year ending December 31, 2025, with 52.60% growth. This brings the company's revenue in the last twelve months to 16.28M, up 4,823.49% year-over-year. In the fiscal year ending June 30, 2025, Radiopharm Theranostics had annual revenue of 12.51M with 538.86% growth.
Revenue (ttm)
16.28M AUD
Revenue Growth
+4,823.49%
P/S Ratio
3.39
Revenue / Employee
1,162,745 AUD
Employees
14
Market Cap
36.76M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 12.51M | 10.55M | 538.86% |
| Jun 30, 2024 | 1.96M | -4.25M | -68.46% |
| Jun 30, 2023 | 6.21M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aligos Therapeutics | 31.52M |
| Veru Inc. | 16.89M |
| Apollomics | 8.84M |
| Dyadic International | 3.81M |
| CervoMed | 2.09M |
| BeyondSpring | 1.88M |
| Nutriband | 1.80M |
| Hyperion DeFi | 1.04M |
RADX News
- 16 days ago - Radiopharm Theranostics (RADX) Secures $4.1M in Direct Offering - GuruFocus
- 16 days ago - Radiopharm announces $4.1M registered direct offering - TheFly
- 16 days ago - Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan - GlobeNewsWire
- 18 days ago - Radiopharm Theranostics Reports Positive Trial Updates For RAD101 And RAD204 - Nasdaq
- 18 days ago - Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy - GlobeNewsWire
- 18 days ago - Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases - GlobeNewsWire
- 18 days ago - Radiopharm Reports Positive Phase 2b Data For RAD101 In Brain Metastases Diagnosis - Nasdaq
- 19 days ago - Radiopharm Theranostics trading halted, news pending - TheFly